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Abstract
Objective. Malaria has been prevalent for a long time in Iran and continues to be a health problem
despite substantial control programs. In addition to numerous cytokines, nitric oxide (NO) is thought
to be a key molecule and a novel target of malaria immunopathology. Material and methods. The
objective of this research was to measure reactive nitrogen intermediates (RNI) as stable metabolites
of NO induction in plasma of malaria-infected patients in Iran. In this study, 235 blood samples from
malaria patients and 80 blood samples from healthy controls were randomly collected from different
malarial endemic provinces of Iran, located in southeastern (Sistan & Balouchestan, Hormozgan,
Kerman) and northwestern (Ardabil) areas. The involvement of NO in malaria patients has been
investigated by statistical analysis of RNI values. Griess micro assay (GMA) was used during
Plasmodium vivax, P. falciparum and mixed infections, in order to evaluate whether RNI changes are
related to the provincial areas, parasite strains, clinical symptoms and age and gender parameters.
Results. The results showed a significant increase of RNI level in malaria patients compared with the
control groups of Ardabil (pv0.01), Sistan & Balouchestan, Hormozgan and Kerman (pv0.001)
provinces. The level of RNI was higher in mixed plasmodial infection than in single infection.
Conclusions. The high level of RNI was dependent on the type of infection, the plasmodia strain, the
clinical symptoms, the age groups and the endemic provinces. Although, this study did not clarify the
pathogenic and/or protective role of NO in malaria, our findings provide a novel immunoepidemio-
logical aspect of basal NO production in patients with malaria in endemic areas in Iran.
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Introduction
Malaria is one of the most important parasitic diseases in the world [1]. It has been
prevalent for a long time in Iran [2] and it is still a problem, despite the national malaria
control program [3]. Out of the 23,562 malaria cases that have been reported in 2003,
more than 70 % occurred in the southeastern (SE) part of the country [1,4]. The inherent
problems are due to the existence of technical and administrative difficulties, drug and
vector resistance and complications regarding the importation of malaria from neighboring
countries [3,5]. Recently, a new threat of malaria importation emerged from the
northwestern (NW) part of the country, the Parsabad area, which was affected by a
serious epidemic of Plasmodium vivax [5]. Iran was divided into two malaria zones north
and south of the Zagros Mountain Range [3] including SE provinces (Sistan &
Balouchestan, Hormozgan and Kerman) and the NW province (Ardabil) [6]. To date,
the malaria situation in the SE corner is serious [4], but in other endemic areas, malaria is
hypoendemic with non-serious cases [7]. P. vivax is the most prevalent species, followed by
P. falciparum [8] and mixed infections [9,10].
Increased drug and insecticide resistance has made vaccine preparation a matter of
urgency for malaria, with the focus on new targets in both parasite and host [11,12].
Potential effector mechanisms of immunity against malaria include antibodies, macro-
phages, T cells, cytokines and a variety of other soluble mediators [13].
Activated phagocytic cells generate large amounts of highly toxic molecules, reactive
oxygen and nitrogen intermediates (ROI, RNI) [14], H2O2, nitric oxide (NO) and at least
80 cytokines and enzymes [15–17]. NO reacts to form biologically active oxides, including
nitrites and nitrates, collectively termed RNI, which react in several ways [18]. In addition
to numerous cytokines [13,19,20], the role of NO as a mediator in clinical malaria remains
controversial [21,22]. Despite the reported protective effects of NO in the early responses
[23,24], some publications do not support a crucial role for NO in immunity against
Plasmodia [25–27].
In previous reports [18,28–30], NO, RNI and NO synthase (NOS) were investigated in
murine Plasmodia, less attention being given to their role in immunoparasitology of human
malaria. Variation in NO levels is under debate; this might elucidate some of the
controversial data obtained with human malaria studies from different locations
[29,31,32]. The aim of this novel immunoepidemiological study was to determine RNI
as stable metabolites of NO activity during infection in malaria patients of endemic areas of
Iran in the eastern Mediterranean region, in order to evaluate whether changes in RNI level
are related to parasite strains, clinical symptoms, age groups, gender and geographical
parameters.
Material and methods
Malaria patients and control groups
In this report we investigated the possible induction of RNI in patients infected with P.
vivax, P. falciparum or mixed infection. This study was conducted from 2002 to 2004 in the
endemic provinces of Hormozgan, Sistan & Balouchestan, Kerman and Ardabil. The
pattern of NO induction was studied among the malaria patients and compared with the
control groups. Two hundred and thirty-five blood samples (55–60 samples/province) were
randomly collected from malaria-confirmed patients (microscopic method) who resided in
the above-mentioned endemic areas (Figure 1). In addition, 80 blood samples (20 samples/
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province) were randomly taken from healthy controls with no new infection and no history
of malaria from the same endemic regions. Sample selection in both groups was applied
considering all statistical parameters including province, gender and age groups.
Microscopic method
Thick and thin blood smears were produced from finger-prick samples; thin smears were
fixed with ethanol, and both smears stained with 10 % Giemsa for 20 min, washed in tap-
water, dried at room temperature (22–25˚C) and observed under light micropscopy. Up to
200 microscopic fields were examined to establish the diagnosis.
Blood samples
Ten milliliters of circulation blood was collected from malaria patients aliquoted in two
tubes; the first tube contained EDTA (Sigma Chemical Co. UK) to extract DNA for
Figure 1. Malaria endemic areas of Iran. The country is divided into two epidemiological zones of malaria in areas
north and south of the Zagros Mountain Range: the southeast (Sistan-Balouchestan, Hormozgan, Kerman
provinces) and the northwest (Ardabil province).
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polymerase chain reaction (PCR) assay, and the second tube, containing heparin 50 IU
(Monoparin; CP Pharmaceuticals Ltd., UK), was used for plasma preparation for Griess
micro assay (GMA).
Nested PCR
PCR assay was used to detect the human malaria parasites [9,10]. Briefly, DNA of all
Plasmodia was extracted by the boiling method from blood containing EDTA and exposed
to first primers including rPLU5 and rPLU6. PCR products were reacted with second
primers, which were specific to prevalent species of human malaria in Iran. The primers in
this study were FAL1, FAL2 (P. falciparum), VIV1, VIV2 (P. vivax) and MAL1, MAL2 (P.
malariae), used according to the method developed by Snounou et al. [33]. DNA was
amplified according to the following thermo-cycling program, denaturing 95˚C 1 min,
annealing 58˚C 2 min and extension 72˚C 2 min for 35 cycles. PCR products were run in a
1.5 % agarose gel, observed by UV transluminator.
Griess micro assay (GMA)
Plasma was prepared by centrifuging the blood at 1500 RCF (MSE Centaur 2, England)
for 10 min and stored at –70˚C until use. RNI levels were measured in plasma as nitrites
using the modified Griess reaction [34] after first converting nitrates to nitrites with nitrate
reductase treatment. Standard curves for sodium nitrite and nitrate (Sigma Chemical Co.)
were prepared. Samples (60 mL) were treated with 10 mL nitrate reductase (NAD[P]H
Aspergillus species 5 U/mL, Sigma Chemical Co.) and 30 mL NADPH b-nicotinamide
adenine dinucleotide phosphate (1.25 mg/mL, Sigma Diagnostics, St. Louis, Mo., USA).
Griess reagent 200 mL (5 % phosphoric acid, 1 % sulfanilic acid and 0.1 % N (1-naphthyl-
1)-ethylendiamine dihydrochloride (NED), all from Sigma Chemical Co., dissolved in
100 mL deionized water) was then added and proteins subsequently precipitated with 200
ml trichloroacetic acid 10 %, (BDH, England). Tube contents were vortex mixed then
centrifuged at 13,400 RCF (Model 1-13 Microcentrifuge; Sigma Chemical Co.). Duplicate
200 mL samples of supernatants were transferred to a 96-well, flat-bottomed microplate
(Costar, USA) and absorbances read at 520 nm using a microplate reader (MS2 Reader;
ICN Flow, UK). Values were calculated from standard calibration plots for NaNO2 and
NaNO3 as previously described [18].
Statistical analysis
Values for RNI concentrations are presented as the mean¡SEM for groups of n samples.
The significance of difference was determined by Student’s t-test using GraphPad Prism
Software (GraphPad, San Diego, Calif., USA).
Results
The results indicated that RNI levels significantly increased in malaria patients living in the
Ardabil (pv0.01), Sistan & Balouchestan, Hormozgan and Kerman (pv0.001) provinces.
Total data of all malaria-endemic regions of Iran showed an increase in RNI level
(pv0.001) in the malarial group compared with the control group (Figures 2, 3).
In each province, the RNI level of malarial patients was compared with that of the related
controls. In this study, higher RNI values rather than average control values were
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Figure 2. Reactive nitrogen intermediate (RNI) concentrations in control and malaria groups of residents in four
endemic provinces of Iran. RNI levels significantly increased in malaria patients of Ardabil (**pv0.01), Sistan &
Balouchestan (***pv0.001), Hormozgan (pv0.001) and Kerman (pv0.001) provinces in comparison with
related controls (mean¡SEM, n555–60 malaria, n520 control samples; samples/province).
Figure 3. Reactive nitrogen intermediate (RNI) production as nitric oxide (NO) pattern in control and malaria
groups of all malaria-endemic areas of Iran. RNI levels significantly increased in all malaria patients of endemic
regions of Iran (***pv0.001) in comparison with the control group (mean¡SEM, n5235 malaria, n580 control
samples).
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considered as NO positive (NO+). The data resulting from analyzing the regression line
indicated different equation values for control (Y50.29X + 26.2) and malaria (Y50.65X +
11.3) groups. The lowest rate of NO+ was observed in Ardabil province (63.3 %) and the
highest rate was found in Hormozgan province (90.9 %). The NO+ rates in Sistan &
Balouchestan and Kerman were 80 % and 88.3 %, respectively. The average percentage of
samples from all malaria patients was 80.4 (Figure 4).
Discussion
In this novel study, the association of NO in malaria by measurement of RNI levels has
been investigated. However, indirect determinations assaying NO metabolites as RNI
could be misleading. Nitrite and nitrate may not solely represent NO activity in the host,
but also that of normal bacterial flora, infections or the nitrate content of the diet [18]. In
this instance, to decrease the research bias, using a control group from residents of the same
region without any history of malaria could be useful.
Both direct and nested PCR diagnosis revealed a relationship between NO+ cases and
type of infection. The highest NO+ rates were among mixed-infection cases (94.9 %) and
the lowest rate was observed in P. falciparum infection (66.9 %). The NO+ rate for P. vivax
infection was reported to be 81 %. A relationship was observed between NO+ cases and
clinical symptoms including fever, tremor, anemia and headache. In the majority of
symptomatic patients (w80 %), high levels of RNI were observed. Lack of hepatosple-
nomegaly and brain disturbances in our patients did not help to clarify the actual role of
NO in malarial symptoms, which needs further study. Increased NO synthesis appears to
have a protective rather than pathological role in malaria. However, pathogenic effects
including cerebral malaria [35], severe anemia [36] or even death [37] may be related to
toxic metabolites of NO overproduction; therefore, the complex relationship between
symptoms, genetic polymorphisms and NO induction in populations requires further study
[38]. In order to evaluate any association between NO and age of malaria patients, different
groups were studied and the values of NO+ cases among them were compared. The NO+
Figure 4. Relative frequency of nitric oxide-(NO) positive and -negative in malarial patients of all endemic areas of
Iran. Significant difference between percentages of NO-positive and -negative cases in malarial patients of endemic
regions of Iran (***pv0.001) (Mean¡SEM, n5235 malaria samples).
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cases in malaria patients were 77.9 % (1–15 years), 69.4 % (16–30 years), 82.1 % (31–45
years) and 94.1 % (over 45 years old). In this study, a relationship between NO and age of
malaria patients was observed. The majority of NO+ cases were more than 45 years of age.
Meanwhile, this concept was connected to the genetic profiles of population and parasite
dominancy. The role of the host’s gender and NO induction was also investigated; the
percentages of NO+ cases in male and female patients were different in the four provinces
studied. In this study, 83.7 % of male malaria patients and 74.7 % of female malaria
patients were NO+, but no significant difference was observed between the two genders.
The low percentage of NO+ cases in the NW province and higher values in the SE
provinces may emphasize a dependency of NO on the region, which indicates a weak
induction role for single infection in the NW region than mixed infection in the SE region.
This may indicate a synergistic effect for mixed Plasmodia infection to induce more NO in
the host, but further investigation is needed to elucidate this concept. The results showed a
significant increase in RNI levels and NO+ cases among malaria patients in Iran. This may
clarify the involvement of NO/RNI during malarial infection in this region, but it cannot be
confirmed whether changes in NO production are beneficial or detrimental to the host.
Notwithstanding the conflicting publications, the role of NO in the immune responses to
Plasmodium remains uncertain [21,36,37,39,40]. NO involvement in malaria is reported to
be varied [29,30], which is related to numerous parameters. Variation in genetic structure
and polymorphisms of genes encoding NOS induction could explain the ability of host
responses to malaria infection in various regions [31,32,37,41]. These variations in
different populations may be consistent with genetic differences in the human profile
[42,43]. The protective polymorphisms may undergo selection in populations with a long
history of exposure to malaria and other infections. Genetic variation in iNOS or related
genes could also contribute to differences in basal NO production in some populations [38]
or may influence susceptibility to and severity of malaria [44]. Conclusively, genetic
epidemiology or cytokine biology alone is not enough to solve the NO paradox, but
together they stand a good chance of doing so [37].
In conclusion, the results of this study indicate that RNI as stable metabolites of NO are
produced in malaria patients of all the endemic provinces of Iran. The rate of this
production is varied and related to the type of infection, clinical symptoms, age groups and
endemic provinces. Although, the present study did not clarify the cytotoxic or protective
role of NO in malaria, it provided immunoepidemiological data on basal NO induction in
both healthy and malaria groups of endemic areas in Iran.
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